Business
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
NEW HAVEN, Conn., April 26, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast to review topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 ‘302’ clinical trial evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males with mild-to-moderate patter
About this update from Veradermics, Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3613,"height":584,"url":"https://media.zenfs.com/en/business-wire.com/045100316bdaea7255fb6b01b5ae80dc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/T0rDxUxz3c40MQpcOaiErg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE1NQ--/https://media.zenfs.com/en/business-wire.com/045100316bdaea7255fb6b01b5ae80dc","width":960,"height":155},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/dNvfeQwj.yv8ReZkXOhs7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zODg-/https://media.zenfs.com/en/business-wire.com/045100316bdaea7255fb6b01b5ae80dc","width":1200,"height":194}},"lazy":false},{"type":"text","content":"Conference call will take place on Monday, April 27, 2026 at 8:00 am ET","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"NEW HAVEN, Conn., April 26, 2026--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast to review topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 ‘302’ clinical trial evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males with mild-to-moderate pattern hair loss.","length":529,"tagName":"p"},{"type":"text","content":"Webcast Details:","length":16,"tagName":"p"},{"type":"text","content":"Time: Monday, April 27, 2026 at 8:00 a.m. ET.Joining: The event and the accompanying slides will be available on the Events page in the Investors section of the company’s website. A replay will be available following the call.","length":227,"tagName":"p"},{"type":"text","content":"About VDPHL01","length":13,"tagName":"p"},{"type":"text","content":"VDPHL01 (extended-release minoxidil tablet) is a proprietary investigational, orally available non-hormonal drug in Phase 3 development for pattern hair loss in both women and men. VDPHL01 leverages extended-release technology to deliver a minoxidil product with the potential for improved efficacy and safety. The proprietary extended-release formulation utilizes a gel matrix designed to deliver long-lasting, steady release of minoxidil for sustained absorption. VDPHL01 has been shown to avoid the...